Barclays Upgrades Medpace Amid AI Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Source: seekingalpha
Medpace Holdings Inc. saw its stock drop by 5.02% as it crossed below the 5-day SMA amid a broader market decline, with the Nasdaq-100 down 1.46% and the S&P 500 down 1.25%.
Barclays upgraded Medpace's rating from Equal-weight to Overweight, asserting that concerns over AI's impact on contract research organizations (CROs) are overstated. The firm believes that the recent sell-off has reset valuations to attractive levels for investors, particularly given Medpace's stock has plummeted over 46% in the past year, making it a compelling entry point.
This upgrade comes at a time when the market is experiencing significant volatility, but analysts remain optimistic about Medpace's potential for recovery, especially as fears regarding AI disruption are deemed exaggerated.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 448.120
Low
462.00
Averages
569.17
High
660.00
Current: 448.120
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Class Action Lawsuit Notification
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its successful track record and expertise in the field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure effective representation in the lawsuit and avoid inexperienced intermediaries.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Medpace Holdings, Inc. and certain officers, alleging violations of federal securities laws from April 22, 2025, to February 9, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that defendants made materially false statements regarding the company's book-to-bill ratio, asserting it was approximately 1.15 during earnings calls, despite having contrary internal information, misleading investors about the company's financial outlook.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by June 5, 2026, allowing them to participate in any potential recovery without needing to serve as lead plaintiffs.
- Law Firm Advantage: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, providing risk-free legal representation for investors, having successfully recovered hundreds of millions for investors nationwide, showcasing their expertise in securities fraud class actions.
See More
Faruqi & Faruqi Investigates Potential Claims Against Medpace Holdings
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased securities between April 22, 2025, and February 9, 2026, urging them to seek lead plaintiff status by the June 8, 2026 deadline.
- False Statements Exposed: The complaint alleges that Medpace's management provided overly positive statements while concealing significant adverse facts regarding the company's backlog cancellation rate, leading to unrealistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Stock Price Volatility: Following the announcement of a fourth-quarter 2025 book-to-bill ratio of 1.04 on February 9, 2026, significantly below the expected 1.15, Medpace's stock price plummeted from $530.35 to $446.05, representing a decline of over 15.9%, resulting in substantial losses for investors.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Medpace's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for affected investors.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws, concerning securities transactions between April 22, 2025, and February 9, 2026, with a deadline for investor contact set for June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses once the market learned the truth, highlighting serious deficiencies in the company's transparency and integrity.
- Legal Proceedings Status: The class action has not yet been certified by the court, meaning investors are not represented by an attorney during this period, and those who choose not to act will remain absent class members, potentially jeopardizing their claims.
- Investor Rights Protection: The Schall Law Firm specializes in securities class actions and encourages affected investors to reach out to discuss their rights, demonstrating a commitment to protecting investor interests and aiming to assist them in recovering losses.
See More
Multiple Companies Face Class Action Lawsuits
- Gossamer Bio Lawsuit: Gossamer Bio is facing allegations for failing to disclose critical facts regarding the failure of its clinical trial from June 16, 2025, to February 20, 2026, which misled investors about the company's prospects, potentially impacting stock prices and investor confidence.
- New Era Energy Issues: New Era Energy is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, which could lead to severe misjudgments of the company's financial health, affecting its market performance.
- Medpace Holdings Allegations: Medpace Holdings is under scrutiny for allegedly inflating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of order cancellations from April 22, 2025, to February 9, 2026, which may undermine investor confidence in the company's future growth.
- Legal Consultation Opportunity: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to file a lead plaintiff motion by the deadlines to protect their rights and seek legal recourse.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Investors are reminded to file a lead plaintiff motion by June 8, 2026, concerning those who purchased Medpace stock between April 22, 2025, and February 9, 2026, highlighting investor concerns over the company's financial performance.
- Financial Miss: Medpace's Q4 2025 financial results released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the expected 1.15, primarily due to backlog cancellations reaching the highest level in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts affecting its business and prospects, harming investor interests.
- Investor Losses: The failure to meet the projected book-to-bill ratio has led to significant losses for investors following the stock price decline, with the lawsuit aiming to seek compensation for affected investors.
See More
Medpace Class Action Lawsuit Notification
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its successful track record and expertise in the field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure effective representation in the lawsuit and avoid inexperienced intermediaries.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Medpace Holdings, Inc. and certain officers, alleging violations of federal securities laws from April 22, 2025, to February 9, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that defendants made materially false statements regarding the company's book-to-bill ratio, asserting it was approximately 1.15 during earnings calls, despite having contrary internal information, misleading investors about the company's financial outlook.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by June 5, 2026, allowing them to participate in any potential recovery without needing to serve as lead plaintiffs.
- Law Firm Advantage: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, providing risk-free legal representation for investors, having successfully recovered hundreds of millions for investors nationwide, showcasing their expertise in securities fraud class actions.
See More
Faruqi & Faruqi Investigates Potential Claims Against Medpace Holdings
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased securities between April 22, 2025, and February 9, 2026, urging them to seek lead plaintiff status by the June 8, 2026 deadline.
- False Statements Exposed: The complaint alleges that Medpace's management provided overly positive statements while concealing significant adverse facts regarding the company's backlog cancellation rate, leading to unrealistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Stock Price Volatility: Following the announcement of a fourth-quarter 2025 book-to-bill ratio of 1.04 on February 9, 2026, significantly below the expected 1.15, Medpace's stock price plummeted from $530.35 to $446.05, representing a decline of over 15.9%, resulting in substantial losses for investors.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Medpace's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for affected investors.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws, concerning securities transactions between April 22, 2025, and February 9, 2026, with a deadline for investor contact set for June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses once the market learned the truth, highlighting serious deficiencies in the company's transparency and integrity.
- Legal Proceedings Status: The class action has not yet been certified by the court, meaning investors are not represented by an attorney during this period, and those who choose not to act will remain absent class members, potentially jeopardizing their claims.
- Investor Rights Protection: The Schall Law Firm specializes in securities class actions and encourages affected investors to reach out to discuss their rights, demonstrating a commitment to protecting investor interests and aiming to assist them in recovering losses.
See More
Multiple Companies Face Class Action Lawsuits
- Gossamer Bio Lawsuit: Gossamer Bio is facing allegations for failing to disclose critical facts regarding the failure of its clinical trial from June 16, 2025, to February 20, 2026, which misled investors about the company's prospects, potentially impacting stock prices and investor confidence.
- New Era Energy Issues: New Era Energy is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, which could lead to severe misjudgments of the company's financial health, affecting its market performance.
- Medpace Holdings Allegations: Medpace Holdings is under scrutiny for allegedly inflating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of order cancellations from April 22, 2025, to February 9, 2026, which may undermine investor confidence in the company's future growth.
- Legal Consultation Opportunity: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to file a lead plaintiff motion by the deadlines to protect their rights and seek legal recourse.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Investors are reminded to file a lead plaintiff motion by June 8, 2026, concerning those who purchased Medpace stock between April 22, 2025, and February 9, 2026, highlighting investor concerns over the company's financial performance.
- Financial Miss: Medpace's Q4 2025 financial results released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the expected 1.15, primarily due to backlog cancellations reaching the highest level in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts affecting its business and prospects, harming investor interests.
- Investor Losses: The failure to meet the projected book-to-bill ratio has led to significant losses for investors following the stock price decline, with the lawsuit aiming to seek compensation for affected investors.
See More
